Sec. 10. If: (1) the federal government indicates that the federal government will withdraw all federal funds from a health care facility for allowing chymopapain to be used within the facility; and (2) providing or allowing use of chymopapain within the facility would jeopardize the receipt of: (A) federal funds for reimbursement for Medicare or Medicaid for all persons within the facility; or (B) construction funds provided by the federal government under the Hill-Burton Hospital Construction Program (42 U.S.C. 291 et seq.) or under Title XVI of the Public Health Services Act (42 U.S.C. 300q-300t); the hospital or other health care facility may prohibit the use of chymopapain within the hospital or facility. [Pre-1993 Recodification Citation: 16-8-10-7(b).] IC 16-42-25 Chapter 25. Drugs: Biosimilar Biological Products 16-42-25-1 "Biological product" 16-42-25-2 "Biosimilar" 16-42-25-3 "Interchangeable" 16-42-25-4 Substitution; conditions 16-42-25-5 Records of dispensing biologic product; time frame; exception 16-42-25-6 Record retention; pharmacy; prescribing practitioner 16-42-25-7 Link to current list of interchangeable biological products; rules 16-42-25-8 Compliance with prescription requirements
‹ Prev All Indiana sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.